Loading
Prostate Cancer Treatment and Research / Epigenetics and DNA Methylation / Ferroptosis and Cancer Prognosis · Journal article
Oncogenesis · August 11, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study proposing that disruption of the AR/ZNF217/PROM2 axis sensitizes prostate cancer cells to ferroptosis and enhances response to enzalutamide in cultured and animal models. The work identifies a novel signaling pathway and demonstrates synergistic effects of RSL3 and enzalutamide in vitro and in vivo, but lacks human subject data or phase-appropriate clinical evidence.
Preclinical mechanistic study with functional assays, drug screening, and xenograft models. Prostate cancer cell lines and animal models; no human subjects enrolled.. Intervention: ZNF217 silencing and overexpression; RSL3 treatment; combined RSL3 and enzalutamide.. Compared with: Control cells and vehicle-treated animals..
ZNF217 identified as a direct AR downstream target aberrantly upregulated in prostate cancer and associated with poor clinical outcomes. ZNF217 silencing markedly amplifies ferroptotic features; ZNF217 overexpression partially alleviates ferroptosis-induced cellular damage. RSL3 identified from a screening panel of 13 ferroptosis inducers as potently suppressing ZNF217 expression.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This hypothesis-generating work suggests a molecular rationale for combination therapy targeting AR/ZNF217/PROM2 and ferroptosis in castration-resistant prostate cancer, but requires clinical validation before informing treatment decisions.
Mechanistic study identifying a signaling pathway and demonstrating synergy in preclinical models, but lacking clinical evidence or phase-appropriate human trials to support clinical practice.
As stated by the source record.
Quoted from the source exactly as published.
This hypothesis-generating work suggests a molecular rationale for combination therapy targeting AR/ZNF217/PROM2 and ferroptosis in castration-resistant prostate cancer, but requires clinical validation before informing treatment decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Dysregulation of androgen receptor (AR) signaling is a key molecular driver of prostate cancer development and its transition to castration-resistant disease. Although emerging evidence indicates that AR may influence ferroptosis by modulating lipid peroxidation and antioxidant systems, the complete transcriptional network through which AR regulates ferroptosis remains incompletely defined. In this study, we identify the transcription factor ZNF217 as a direct downstream target of AR, which is aberrantly upregulated in prostate cancer and associated with poor clinical outcomes. ZNF217 enhances the transcriptional activity of its downstream effector PROM2, thereby suppressing ferroptosis and promoting cell survival. Functional assays demonstrate that ZNF217 silencing markedly amplifies ferroptotic features, whereas ZNF217 overexpression partially alleviates ferroptosis-induced cellular damage. Building on these findings, we established a drug screening system based on ZNF217 expression and identified the compound RSL3 from a panel of 13 ferroptosis inducers, which potently suppresses ZNF217 expression. Further investigations revealed that combined treatment with RSL3 and the AR antagonist enzalutamide produced a synergistic antitumor response in cellular and animal models, accompanied by marked attenuation of AR/ZNF217/PROM2 pathway activity and reduced tumor burden. Collectively, these findings identify AR/ZNF217/PROM2 signaling as a central determinant of ferroptotic vulnerability in prostate cancer and suggest that targeting this pathway may enhance sensitivity to AR inhibition, providing a molecular rationale for combination therapy in castration-resistant prostate cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.